Drug intelligence / Profile preview

DL4

Development stage: Preclinical
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

DL4 is a class 1 nanobody that was isolated from an alpaca immunized with the receptor-binding domain (RBD) of SARS-CoV-2. It binds to the SARS-CoV-2 spike protein with picomolar affinity and neutralizes the original SARS-CoV-2 strain. Research has focused on understanding its immune evasion mechanisms against various Omicron variants and on computationally optimizing its binding affinity to the viral RBD. This nanobody has the potential for therapeutic development against COVID-19.

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on DL4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DL4.

Explore the full profile